Gene Expression Profiling of Metaplastic Lineages Identifies CDH17 as a Prognostic Marker in Early Stage Gastric Cancer

Gastroenterology

Volumn 139, Issue 1, 2010, Pages

  Lee, Hyuk Joon ^a,b   Nam, Ki Taek ^a,c   Park, Heae Surng ^b   Kim, Min A ^b   LaFleur, Bonnie J ^d   Aburatani, Hiroyuki ^e   Yang, Han Kwang ^b   Kim, Woo Ho ^b   Goldenring, James R ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Seoul National University College of Medicine   (South Korea)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

CDH 17; Gastric Cancer; Metaplasia; MUC13

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE 1 B10; ANGIOTENSIN CONVERTING ENZYME 2; BIOLOGICAL MARKER; CADHERIN; CADHERIN 17; COMPLEMENTARY DNA; CYTOKERATIN 20; DIFFUSE PANBRONCHIOLITIS CRITICAL REGION 1 PROTEIN; GALECTIN 4; LYSOZYME; MUCIN 13; MUCIN 5AC; OLFACTOMEDIN 4; PROTEIN REG4; UNCLASSIFIED DRUG;

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE ASSOCIATION; DNA MICROARRAY; EARLY CANCER; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; METAPLASIA; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER; UPREGULATION;

EID: 77953905096     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.04.008     Document Type: Article

References (45)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Sasako M., Sano T., Yamamoto S., et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359 (2008) 453-462
3. Sakuramoto S., Sasako M., Yamaguchi T., et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357 (2007) 1810-1820
4. Yasui W., Oue N., Aung P.P., et al. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 8 (2005) 86-94
5. Hasegawa S., Furukawa Y., Li M., et al. Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res 62 (2002) 7012-7017
6. Leung S.Y., Chen X., Chu K.M., et al. Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci U S A 99 (2002) 16203-16208
7. Boussioutas A., Li H., Liu J., et al. Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res 63 (2003) 2569-2577
8. Oue N., Hamai Y., Mitani Y., et al. Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res 64 (2004) 2397-2405
9. Vecchi M., Nuciforo P., Romagnoli S., et al. Gene expression analysis of early and advanced gastric cancers. Oncogene 26 (2007) 4284-4294
10. Gutiérrez-González L., and Wright N.A. Biology of intestinal metaplasia in 2008: more than a simple phenotypic alteration. Dig Liver Dis 40 (2008) 510-522
11. Wang T.C., Goldenring J.R., Dangler C., et al. Mice lacking secretory phospholipase A2 show altered apoptosis and differentiation with Helicobacter felis infection. Gastroenterology 114 (1998) 675-689
12. Houghton J., Stoicov C., Nomura S., et al. Gastric cancer originating from bone marrow-derived cells. Science 306 (2004) 1568-1571
13. Schmidt P.H., Lee J.R., Joshi V., et al. Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. Lab Invest 79 (1999) 639-646
14. Yamaguchi H., Goldenring J.R., Kaminishi M., et al. Identification of spasmolytic polypeptide expressing metaplasia (SPEM) in remnant gastric cancer and surveillance postgastrectomy biopsies. Dig Dis Sci 47 (2002) 573-578
15. Nam K.T., Varro A., Coffey R.J., et al. Potentiation of oxyntic atrophy-induced gastric metaplasia in amphiregulin-deficient mice. Gastroenterology 132 (2007) 1804-1819
16. Nozaki K., Ogawa M., Williams J.A., et al. A molecular signature of gastric metaplasia arising in response to acute parietal cell loss. Gastroenterology 134 (2008) 511-522
17. Nam K.T., Lee H.J., Mok H., et al. Amphiregulin-deficient mice develop spasmolytic polypeptide expressing metaplasia and intestinal metaplasia. Gastroenterology 136 (2009) 1288-1296
18. Yoshizawa N., Takenaka Y., Yamaguchi H., et al. Emergence of spasmolytic polypeptide-expressing metaplasia in Mongolian gerbils infected with Helicobacter pylori. Lab Invest 87 (2007) 1265-1276
19. Hochberg Y., and Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 9 (1990) 811-818
20. Leys C.M., Nomura S., Rudzinski E., et al. Expression of Pdx-1 in human gastric metaplasia and gastric adenocarcinoma. Hum Pathol 37 (2006) 1162-1168
21. Shimamura T., Ito H., Shibahara J., Watanabe A., et al. Overexpression of MUC13 is associated with intestinal-type gastric cancer. Cancer Sci 96 (2005) 265-273
22. Grötzinger C., Kneifel J., Patschan D., et al. LI-cadherin: a marker of gastric metaplasia and neoplasia. Gut 49 (2001) 73-81
23. Liu W., Zhu J., Cao L., et al. Expression of hGC-1 is correlated with differentiation of gastric carcinoma. Histopathology 51 (2007) 157-165
24. Reis C.A., David L., Correa P., et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. Cancer Res 59 (1999) 1003-1007
25. Oue N., Mitani Y., Aung P.P., et al. Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma. J Pathol 207 (2005) 185-198
26. Ormsby A.H., Vaezi M.F., Richter J.E., et al. Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus. Gastroenterology 119 (2000) 683-690
27. Hashimoto T., Kusakabe T., Watanabe K., et al. Liver-type fatty acid-binding protein is highly expressed in intestinal metaplasia and in a subset of carcinomas of the stomach without association with the fatty acid synthase status in the carcinoma. Pathobiology 71 (2004) 115-122
28. Ouellette A.J. Paneth cells and innate immunity in the crypt microenvironment. Gastroenterology 113 (1997) 1779-1784
29. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355 (2006) 11-20
30. Mirza A.N., Mirza N.Q., Vlastos G., et al. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 235 (2002) 10-26
31. Meining A., Morgner A., Miehlke S., et al. Atrophy-metaplasia-dysplasia-carcinoma sequence in the stomach: a reality or merely a hypothesis?. Best Pract Res Clin Gastroenterol 15 (2001) 983-998
32. Gessner R., and Tauber R. Intestinal cell adhesion molecules. Liver-intestine cadherin. Ann N Y Acad Sci 915 (2000) 136-143
33. Ito R., Oue N., Yoshida K., et al. Clinicopathological significant and prognostic influence of cadherin-17 expression in gastric cancer. Virchows Arch 447 (2005) 717-722
34. Ko S., Chu K.M., Luk J.M., et al. CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach. J Pathol 205 (2005) 615-622
35. Park S.S., Kang S.H., Park J.M., et al. Expression of liver-intestine cadherin and its correlation with lymph node metastasis in gastric cancer: can it predict N stage preoperatively?. Ann Surg Oncol 14 (2007) 94-99
36. Ge J., Chen Z., Wu S., et al. A clinicopathological study on the expression of cadherin-17 and caudal-related homeobox transcription factor (CDX2) in human gastric carcinoma. Clin Oncol (R Coll Radiol) 20 (2008) 275-283
37. Williams S.J., Wreschner D.H., Tran M., et al. Muc13, a novel human cell surface mucin expressed by epithelial and hemopoietic cells. J Biol Chem 276 (2001) 18327-18336
38. Walsh M.D., Young J.P., Leggett B.A., et al. The MUC13 cell surface mucin is highly expressed by human colorectal carcinomas. Hum Pathol 38 (2007) 883-892
39. Chauhan S.C., Vannatta K., Ebeling M.C., et al. Expression and functions of transmembrane mucin MUC13 in ovarian cancer. Cancer Res 69 (2009) 765-774
40. Zhang J., Liu W.L., Tang D.C., et al. Identification and characterization of a novel member of olfactomedin-related protein family, hGC-1, expressed during myeloid lineage development. Gene 283 (2002) 83-93
41. Zhang X., Huang Q., Yang Z., et al. GW112, a novel antiapoptotic protein that promotes tumor growth. Cancer Res 64 (2004) 2474-2481
42. Koshida S., Kobayashi D., Moriai R., et al. Specific overexpression of OLFM4 (GW112/HGC-1) mRNA in colon, breast and lung cancer tissues detected using quantitative analysis. Cancer Sci 98 (2007) 315-320
43. van der Flier L.G., Haegebarth A., Stange D.E., et al. OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells. Gastroenterology 137 (2009) 15-17
44. +ve stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 6 (2010) 25-36
45. Oue N., Sentani K., Noguchi T., et al. Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. Int J Cancer 125 (2009) 2383-2392